The IHU of Marseille is under fire for its use of hydroxychloroquine. The drug is used to treat patients with cancer.
It has been linked to a number of deaths, including that of a patient who died of a heart attack. The trial was to be the first of its kind in France, but was delayed by a year. It is now back on track, but with a new set of conditions. The new condition is that the trial must be completed by the end of the year.